Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer: A hypothesis-generating study

Agnese Barnabei, Lidia Strigari, Agnese Persichetti, Roberto Baldelli, Laura Rizza, Claudia Annoscia, Rosa Lauretta, Giovanni Cigliana, Maddalena Barba, Aurora De Leo, Marialuisa Appetecchia, Francesco Torino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Recombinant human TSH (rhTSH) is currently used in follow-up of patients affected by differentiated thyroid cancer (DTC). Age, sex, weight, body mass index, body surface area (BSA) and renal function are known factors affecting serum TSH peak levels, but the proper rhTSH dose to deliver to single patient remains elusive. In this study, the correlations of basal metabolic rates with serum TSH peak following rhTSH administration were investigated. Methods: We evaluated 221 patients affected by thyroid cancer that received a standard dose rhTSH. Blood samples were collected at pre-established time points. Data on body weight, height, and BSA were collected. The Mifflin-St Jeor and Fleisch equations were used to assess basal metabolism. Results: The median value (range) of serum TSH peaks was 142 ± 53 μU/ml. Serum TSH peaks were significantly lower in males than in females (p = 0.04). TSH values also increased with age. Data showed a significant decrease of TSH peak levels at day 3 from the administration of rhTSH when basal metabolic rates increased (p = 0.002 and p = 0.009, respectively). Similar findings were observed at day 5 (p = 0.004 and p = 0.04, respectively). A multivariate analysis of several factors revealed that patients' basal metabolism (obtained using the Mifflin-St Jeor but not Fleisch equation) predicts serum TSH level peak at day 3 (p < 0.001). These results were used to generate a new formula based on Mifflin-StJeor equation which reveals as a promising tool in tailoring rhTSH dose. Conclusion: Basal metabolism appears an improving factor in tailoring diagnostic rhTSH dose in patients affected by DTC.

Original languageEnglish
Pages (from-to)37
JournalFrontiers in Endocrinology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - Feb 15 2018

Fingerprint

Thyrotropin Alfa
Basal Metabolism
Thyroid Neoplasms
Serum
Body Surface Area
Body Height
Body Mass Index
Multivariate Analysis
Body Weight
Kidney
Weights and Measures

Keywords

  • Basal metabolism
  • Body mass index
  • Recombinant human TSH
  • Sex
  • Thyroid cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer : A hypothesis-generating study. / Barnabei, Agnese; Strigari, Lidia; Persichetti, Agnese; Baldelli, Roberto; Rizza, Laura; Annoscia, Claudia; Lauretta, Rosa; Cigliana, Giovanni; Barba, Maddalena; De Leo, Aurora; Appetecchia, Marialuisa; Torino, Francesco.

In: Frontiers in Endocrinology, Vol. 9, No. FEB, 15.02.2018, p. 37.

Research output: Contribution to journalArticle

Barnabei, Agnese ; Strigari, Lidia ; Persichetti, Agnese ; Baldelli, Roberto ; Rizza, Laura ; Annoscia, Claudia ; Lauretta, Rosa ; Cigliana, Giovanni ; Barba, Maddalena ; De Leo, Aurora ; Appetecchia, Marialuisa ; Torino, Francesco. / Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer : A hypothesis-generating study. In: Frontiers in Endocrinology. 2018 ; Vol. 9, No. FEB. pp. 37.
@article{370437a30803480fa4f82101c53d2b2b,
title = "Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer: A hypothesis-generating study",
abstract = "Purpose: Recombinant human TSH (rhTSH) is currently used in follow-up of patients affected by differentiated thyroid cancer (DTC). Age, sex, weight, body mass index, body surface area (BSA) and renal function are known factors affecting serum TSH peak levels, but the proper rhTSH dose to deliver to single patient remains elusive. In this study, the correlations of basal metabolic rates with serum TSH peak following rhTSH administration were investigated. Methods: We evaluated 221 patients affected by thyroid cancer that received a standard dose rhTSH. Blood samples were collected at pre-established time points. Data on body weight, height, and BSA were collected. The Mifflin-St Jeor and Fleisch equations were used to assess basal metabolism. Results: The median value (range) of serum TSH peaks was 142 ± 53 μU/ml. Serum TSH peaks were significantly lower in males than in females (p = 0.04). TSH values also increased with age. Data showed a significant decrease of TSH peak levels at day 3 from the administration of rhTSH when basal metabolic rates increased (p = 0.002 and p = 0.009, respectively). Similar findings were observed at day 5 (p = 0.004 and p = 0.04, respectively). A multivariate analysis of several factors revealed that patients' basal metabolism (obtained using the Mifflin-St Jeor but not Fleisch equation) predicts serum TSH level peak at day 3 (p < 0.001). These results were used to generate a new formula based on Mifflin-StJeor equation which reveals as a promising tool in tailoring rhTSH dose. Conclusion: Basal metabolism appears an improving factor in tailoring diagnostic rhTSH dose in patients affected by DTC.",
keywords = "Basal metabolism, Body mass index, Recombinant human TSH, Sex, Thyroid cancer",
author = "Agnese Barnabei and Lidia Strigari and Agnese Persichetti and Roberto Baldelli and Laura Rizza and Claudia Annoscia and Rosa Lauretta and Giovanni Cigliana and Maddalena Barba and {De Leo}, Aurora and Marialuisa Appetecchia and Francesco Torino",
year = "2018",
month = "2",
day = "15",
doi = "10.3389/fendo.2018.00037",
language = "English",
volume = "9",
pages = "37",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer

T2 - A hypothesis-generating study

AU - Barnabei, Agnese

AU - Strigari, Lidia

AU - Persichetti, Agnese

AU - Baldelli, Roberto

AU - Rizza, Laura

AU - Annoscia, Claudia

AU - Lauretta, Rosa

AU - Cigliana, Giovanni

AU - Barba, Maddalena

AU - De Leo, Aurora

AU - Appetecchia, Marialuisa

AU - Torino, Francesco

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Purpose: Recombinant human TSH (rhTSH) is currently used in follow-up of patients affected by differentiated thyroid cancer (DTC). Age, sex, weight, body mass index, body surface area (BSA) and renal function are known factors affecting serum TSH peak levels, but the proper rhTSH dose to deliver to single patient remains elusive. In this study, the correlations of basal metabolic rates with serum TSH peak following rhTSH administration were investigated. Methods: We evaluated 221 patients affected by thyroid cancer that received a standard dose rhTSH. Blood samples were collected at pre-established time points. Data on body weight, height, and BSA were collected. The Mifflin-St Jeor and Fleisch equations were used to assess basal metabolism. Results: The median value (range) of serum TSH peaks was 142 ± 53 μU/ml. Serum TSH peaks were significantly lower in males than in females (p = 0.04). TSH values also increased with age. Data showed a significant decrease of TSH peak levels at day 3 from the administration of rhTSH when basal metabolic rates increased (p = 0.002 and p = 0.009, respectively). Similar findings were observed at day 5 (p = 0.004 and p = 0.04, respectively). A multivariate analysis of several factors revealed that patients' basal metabolism (obtained using the Mifflin-St Jeor but not Fleisch equation) predicts serum TSH level peak at day 3 (p < 0.001). These results were used to generate a new formula based on Mifflin-StJeor equation which reveals as a promising tool in tailoring rhTSH dose. Conclusion: Basal metabolism appears an improving factor in tailoring diagnostic rhTSH dose in patients affected by DTC.

AB - Purpose: Recombinant human TSH (rhTSH) is currently used in follow-up of patients affected by differentiated thyroid cancer (DTC). Age, sex, weight, body mass index, body surface area (BSA) and renal function are known factors affecting serum TSH peak levels, but the proper rhTSH dose to deliver to single patient remains elusive. In this study, the correlations of basal metabolic rates with serum TSH peak following rhTSH administration were investigated. Methods: We evaluated 221 patients affected by thyroid cancer that received a standard dose rhTSH. Blood samples were collected at pre-established time points. Data on body weight, height, and BSA were collected. The Mifflin-St Jeor and Fleisch equations were used to assess basal metabolism. Results: The median value (range) of serum TSH peaks was 142 ± 53 μU/ml. Serum TSH peaks were significantly lower in males than in females (p = 0.04). TSH values also increased with age. Data showed a significant decrease of TSH peak levels at day 3 from the administration of rhTSH when basal metabolic rates increased (p = 0.002 and p = 0.009, respectively). Similar findings were observed at day 5 (p = 0.004 and p = 0.04, respectively). A multivariate analysis of several factors revealed that patients' basal metabolism (obtained using the Mifflin-St Jeor but not Fleisch equation) predicts serum TSH level peak at day 3 (p < 0.001). These results were used to generate a new formula based on Mifflin-StJeor equation which reveals as a promising tool in tailoring rhTSH dose. Conclusion: Basal metabolism appears an improving factor in tailoring diagnostic rhTSH dose in patients affected by DTC.

KW - Basal metabolism

KW - Body mass index

KW - Recombinant human TSH

KW - Sex

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85042496168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042496168&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00037

DO - 10.3389/fendo.2018.00037

M3 - Article

AN - SCOPUS:85042496168

VL - 9

SP - 37

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - FEB

ER -